Innova Captab Resolves ₹15.8 Crore CGST Demand

Innova Captab Limited announced the cancellation of a ₹15.81 crore demand proposed by the CGST authority. An Order-in-Original, dated April 14, 2026, officially dropped all proceedings related to a Show Cause cum Demand Notice (SCN) previously issued. The company confirmed there is no outstanding financial liability stemming from this matter, marking its definitive closure.

Impact of the Resolution

This outcome removes a significant financial and regulatory concern for Innova Captab. With the tax matter resolved, the company gains regulatory clarity and can now fully concentrate on its core business operations and growth strategies. This development is positive for the company's financial standing and investor confidence.

Background of the Tax Notice

The issue stemmed from a Show Cause cum Demand Notice (SCN) issued by the CGST Commissionerate, Shimla, on October 15, 2025. The notice alleged claims for excess refund of accumulated Input Tax Credit (ITC) between May 2020 and March 2024, proposing a demand of approximately ₹15.81 crore, plus interest and penalties. Innova Captab had contested the notice, asserting its claims had no merit and preparing to present its defense.

Key Changes Following Resolution

• Innova Captab faces no financial liability or penalty related to the CGST demand.
• The regulatory issue concerning the ITC refund claims is officially closed.
• The company's financial statements will not be impacted by this previous demand.
• Management focus and resources can now be fully directed towards business expansion and operational efficiency.

Remaining Risks

This filing does not highlight new risks. The resolved tax matter was the primary concern previously identified.

Sector Context: Tax Compliance in Pharma

Other major Indian pharmaceutical companies, including Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, and Lupin Ltd, also operate in a complex regulatory environment. Like Innova Captab, these firms must manage stringent compliance with Goods and Services Tax (GST) and other regulations, facing potential scrutiny on areas such as input tax credit claims. The sector has seen several firms investigated for GST compliance issues, highlighting its sensitivity to tax matters.

Looking Ahead

• Continued strong financial performance and revenue growth from Innova Captab's core CDMO and branded generics businesses.
• Management commentary on future expansion plans and market strategies.
• Ongoing adherence to all regulatory and tax compliance requirements.
• The company's ability to leverage its clear regulatory status for further business development.